-- Swiss Stocks Advance; Julius Baer, UBS Shares Lead SMI Benchmark Higher
-- B y   A d a m   H a i g h
-- 2010-12-01T16:49:06Z
-- http://www.bloomberg.com/news/2010-12-01/swiss-stocks-advance-julius-baer-ubs-shares-lead-smi-higher.html
Swiss stocks  advanced, with the
benchmark Swiss Market Index rebounding from its lowest level
since October, as banking shares climbed after three days of
losses.  Julius Baer Group Ltd.  gained 5.6 percent and UBS AG rose
2.9 percent in Zurich. Galenica AG rallied the most since 2008
after saying its Vifor Pharma unit and Fresenius Medical Care
will strengthen an existing partnership to form a pharmaceutical
company focused on renal care.  The SMI gained 97.27, or 1.5 percent, to 6,409.70 at the
5:30 p.m. close in Zurich. The gauge had fallen to its lowest
level since October this week after a European Union-led bailout
of Ireland failed to reassure investors that the region will
contain its sovereign-debt crisis. Still, the measure had
rallied 7.9 percent from its 2010 low in July as investors
anticipated the decision by the Federal Reserve in November to
unveil another round of bond purchases to boost the world’s
largest economy.  Sovereign debt concern “remains an issue in the background
but this liquidity that is coming through will probably takeover
in the reasonably near future and we’ll see markets rebound,”
Philip Poole, the global head of macro and investment strategy
at HSBC Global Asset Management, which manages $411 billion in
London, said in a Bloomberg Television interview with Andrea
Catherwood.  The broader Swiss Performance Index climbed 1.6 percent to
5,742.99 today. The banks gauge on the Stoxx 600 Europe Index,
which has fallen for the past three days, today gained the most
since August.  Julius Baer, UBS  Julius Baer gained 5.6 percent to 40.2 Swiss francs. UBS
climbed 2.9 percent to 15.47 francs.  Galenica, the Swiss drug wholesaler, rallied 8.2 percent to
530 francs.  Novartis AG gained 1.8 percent to 54.2 francs. Chief
Executive Officer Joe Jimenez said he sees more pressure on drug
prices in the months to come, and the Swiss drugmaker will
continue to reduce expenses. He spoke at a Financial Times drug
industry conference in London today.  To contact the reporter on this story:
Adam Haigh in London at 
 ahaigh1@bloomberg.net .  To contact the editor responsible for this story:
David Merritt at   dmerritt1@bloomberg.net . 